AU2022267389A1 - Dosing regimens of peptide conjugates of topoisomerase i inhibitors - Google Patents
Dosing regimens of peptide conjugates of topoisomerase i inhibitors Download PDFInfo
- Publication number
- AU2022267389A1 AU2022267389A1 AU2022267389A AU2022267389A AU2022267389A1 AU 2022267389 A1 AU2022267389 A1 AU 2022267389A1 AU 2022267389 A AU2022267389 A AU 2022267389A AU 2022267389 A AU2022267389 A AU 2022267389A AU 2022267389 A1 AU2022267389 A1 AU 2022267389A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- administered
- pharmaceutically acceptable
- acceptable salt
- daily dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181640P | 2021-04-29 | 2021-04-29 | |
| US63/181,640 | 2021-04-29 | ||
| PCT/US2022/071967 WO2022232808A1 (en) | 2021-04-29 | 2022-04-28 | Dosing regimens of peptide conjugates of topoisomerase i inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2022267389A1 true AU2022267389A1 (en) | 2023-11-09 |
| AU2022267389A9 AU2022267389A9 (en) | 2023-11-16 |
Family
ID=81749580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022267389A Pending AU2022267389A1 (en) | 2021-04-29 | 2022-04-28 | Dosing regimens of peptide conjugates of topoisomerase i inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240226308A1 (https=) |
| EP (1) | EP4329817A1 (https=) |
| JP (1) | JP2024516825A (https=) |
| KR (1) | KR20240019097A (https=) |
| CN (1) | CN117897175A (https=) |
| AU (1) | AU2022267389A1 (https=) |
| CA (1) | CA3218253A1 (https=) |
| CL (1) | CL2023003187A1 (https=) |
| IL (1) | IL308052A (https=) |
| MX (1) | MX2023012779A (https=) |
| TW (1) | TW202308696A (https=) |
| WO (1) | WO2022232808A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000449A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
| US11555019B2 (en) | 2019-07-10 | 2023-01-17 | Cybrexa 3, Inc. | Peptide conjugates of microtubule-targeting agents as therapeutics |
| WO2025186213A1 (en) | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006078816A2 (en) | 2005-01-18 | 2006-07-27 | The Board Of Governors For Higher Education | Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide |
| EP4321168A3 (en) | 2010-07-13 | 2024-04-24 | Yale University, Inc. | Environmentally sensitive compositions |
| KR20200121800A (ko) | 2018-01-05 | 2020-10-26 | 싸이브렉사 1, 인크. | 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법 |
| MX2022000449A (es) * | 2019-07-10 | 2022-04-25 | Cybrexa 2 Inc | Conjugados peptídicos de citotoxinas como terapéuticos. |
-
2022
- 2022-04-28 CN CN202280044027.3A patent/CN117897175A/zh active Pending
- 2022-04-28 CA CA3218253A patent/CA3218253A1/en active Pending
- 2022-04-28 MX MX2023012779A patent/MX2023012779A/es unknown
- 2022-04-28 TW TW111116202A patent/TW202308696A/zh unknown
- 2022-04-28 AU AU2022267389A patent/AU2022267389A1/en active Pending
- 2022-04-28 EP EP22724607.1A patent/EP4329817A1/en active Pending
- 2022-04-28 IL IL308052A patent/IL308052A/en unknown
- 2022-04-28 JP JP2023566472A patent/JP2024516825A/ja active Pending
- 2022-04-28 US US18/288,650 patent/US20240226308A1/en active Pending
- 2022-04-28 WO PCT/US2022/071967 patent/WO2022232808A1/en not_active Ceased
- 2022-04-28 KR KR1020237040934A patent/KR20240019097A/ko active Pending
-
2023
- 2023-10-25 CL CL2023003187A patent/CL2023003187A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20240226308A1 (en) | 2024-07-11 |
| CL2023003187A1 (es) | 2024-05-03 |
| MX2023012779A (es) | 2024-01-16 |
| IL308052A (en) | 2023-12-01 |
| JP2024516825A (ja) | 2024-04-17 |
| CN117897175A (zh) | 2024-04-16 |
| WO2022232808A1 (en) | 2022-11-03 |
| EP4329817A1 (en) | 2024-03-06 |
| KR20240019097A (ko) | 2024-02-14 |
| TW202308696A (zh) | 2023-03-01 |
| CA3218253A1 (en) | 2022-11-03 |
| AU2022267389A9 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240226308A1 (en) | Dosing regimens of peptide conjugates of topoisomerase i inhibitors | |
| TW202038957A (zh) | 抗體-藥物結合物與激酶抑制劑之組合 | |
| AU2011325989C1 (en) | Methods of treating cancer | |
| ES2933266T3 (es) | Administración de múltiples bolos de [6R] MTHF en una quimioterapia basada en 5-fluorouracilo | |
| JP6425653B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2021505548A (ja) | 化学療法抵抗性の卵巣がんまたは乳がんの治療におけるｐａｒｐ阻害剤の使用 | |
| CN112587666A (zh) | 用于治疗癌症的pd-1/pd-l1相互作用的小分子抑制剂和抗pd-1抗体的组合 | |
| JP2017530129A (ja) | ツブリシン複合体を用いた癌の治療方法 | |
| KR20220003560A (ko) | 유잉 육종의 치료를 위한 퀴놀린 화합물 또는 그의 약제학적으로 허용 가능한 염 | |
| JP2014515390A (ja) | Ｐｉ３ｋ阻害剤化合物を用いた中皮腫の治療法 | |
| KR20200078483A (ko) | 간암 치료를 위한 조성물 및 방법 | |
| CN114302745A (zh) | 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法 | |
| US20230116137A1 (en) | Methods for treating colorectal and metastatic colorectal cancers | |
| JPWO2019176984A1 (ja) | 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット | |
| AU2018234141A1 (en) | Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator | |
| US20250360124A1 (en) | Novel ras inhibitors | |
| Metzger et al. | Intraportal chemotherapy for colorectal hepatic metastases | |
| RU2777595C2 (ru) | Препарат и композиция для лечения злокачественных опухолей | |
| WO2024258916A1 (en) | Stat3 degraders and uses thereof | |
| WO2024255883A1 (zh) | Akt抑制剂在制备预防或治疗乳腺癌药物中的用途 | |
| WO2024255830A1 (zh) | Akt抑制剂在制备预防或治疗卵巢癌药物中的用途 | |
| AU2026201789A1 (en) | Therapeutic combinations of orally administered paclitaxel, a p-gp inhibitor, and a checkpoint inhibitor for the treatment of solid tumors | |
| Tolcher et al. | 403 POSTER Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: preliminary report from a multi-institutional phase-1b clinical trial | |
| EP3976036A1 (en) | Methods and uses for treating cancer | |
| HK40040066B (en) | Administration of multiple boluses of [6r] mthf in a 5-fluorouracil-based chemotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SREP | Specification republished |